The Medically Associated Science and Technology (MAST) program at Cedars-Sinaiis dedicated
to the development of novel drugs and devices to diagnose and treat patients.
MAST represents the mainsail of a vessel taking us on a voyage of discovery in medicine and science. This innovative program is working to develop new diagnostics and therapeutics to treat patients with illnesses related to imbalances or alterations in the microbiome. Over the last 20 years, the MAST team has made many discoveries that benefit millions of patients, and we hope to help millions more with our growing fleet of novel diagnostics and therapeutics.
At MAST, patients are at the center of our work, which gives us a unique perspective as we innovate. Having direct interactions with patients drives our curiosity toward clinically meaningful questions and allows us to move quickly toward identifiable solutions. The MAST team brings expertise in working with the microbiome in both basic and clinical aspects, along with a track record of navigating the U.S. Food and Drug Administration (FDA) approval process and post-FDA approval work.
The microbiome is the cluster of bacteria and flora that live within us, and can influence our health and wellbeing. The MAST program is determined to study the gut microbiome using lab research and clinical studies.
Learn more about the research and advances in the MAST program.